Synthesis, structural studies, cytotoxicity and computational evaluation of 1,3,4-oxadiazolyl-thio-oxazines as potential NF-κB inhibitors in breast cancer

Key Points

• Inhibition of NF-kB activity may enhance treatment outcomes in breast cancer, driving further investigation.
• Cytotoxicity assays showed that specific oxadiazolyl-thio-oxazines significantly reduced cancer cell viability.
• Assessment using computational evaluation highlighted promising structural features of the compound class.
• Findings indicate a need for further investigation to optimize these inhibitors for therapeutic use.